DARE Daré Bioscience, Inc.
Healthcare$2.34-1.27%ClosedMarket Cap: $22.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
46.86
P/S
19.50
EV/EBITDA
-1.13
DCF Value
$0.17
FCF Yield
-45.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
5.6%
Operating Margin
-1034.4%
Net Margin
-1038.8%
ROE
763.4%
ROA
-43.2%
ROIC
-151.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $152.5K | -422.8% | $-3.0M | $-3.0M | $— | — |
| Q4 null | $1.0M | 71.1% | $-1.5M | $-1.4M | $— | — |
| FY null | $1.0M | -137.5% | $-13.6M | $-13.4M | $— | — |
| Q3 null | $2.3K | 100.0% | $-3.7M | $-3.6M | $— | — |
| Q2 null | $-21.2K | 100.0% | $-3.8M | $-4.0M | $— | — |
| Q1 null | $25.4K | -8935.2% | $-4.6M | $-4.4M | $— | — |
| Q4 null | $-63.6K | 22446.0% | $-5.4M | $-5.5M | $— | — |
| FY null | $9.8K | -146110.2% | $-23.5M | $-4.1M | $— | — |
| Q3 null | $41.7K | 40.0% | $-4.7M | $-4.7M | $— | — |
| Q2 null | $22.4K | 100.0% | $-7.4M | $12.9M | $— | — |
| Q1 null | $9.3K | -36034.1% | $-6.0M | $-6.8M | $— | — |
| Q4 2023 | $1.8M | -1092.7% | $-5.2M | $-5.1M | $-0.69 | — |